Tozorakimab Demonstrates Efficacy in Latest COPD Phase III Trial

AstraZeneca has reported positive results from a third Phase III study of tozorakimab in chronic obstructive pulmonary disease (COPD), reinforcing its potential as a novel treatment option.

In the MIRANDA trial, the therapy significantly reduced the annual rate of moderate-to-severe exacerbations in both former smokers and the broader patient population. Participants received tozorakimab alongside standard care every two weeks, targeting those who continued to experience exacerbations despite existing inhaled treatments.

These findings build on earlier Phase III trials, which also showed consistent reductions in exacerbation rates across diverse patient groups. Tozorakimab, a monoclonal antibody targeting interleukin-33, demonstrated a favourable safety profile.

The drug could become a first-in-class treatment if approved, offering benefits across a wider patient population. AstraZeneca plans to submit the data for regulatory review, as the global COPD treatment market continues to expand rapidly.

21-04-2026